Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Neoplasm Metastasis × entrectinib × Clear all

Phase

Status

Terminated 1 Suspended 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3 Neoplasms 2 Hematologic Neoplasms 2 Solid Tumors 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Neoplasm Metastasis 1 Lymphoproliferative Disorders 1 Locally Advanced Thyroid Gland Carcinoma 1 Glioma 1 Central Nervous System Neoplasms 1 Advanced Thyroid Cancer Patients Who Received Target Therapy 1

Interventions

pembrolizumab 43 Specimen Handling 28 Magnetic Resonance Spectroscopy 24 Biopsy 24 Radiosurgery 17 Gemcitabine 14 Nivolumab 12 Cisplatin 11 Paclitaxel 10 Cyclophosphamide 10 Carboplatin 10 Capecitabine 9 Taxes 8 Pemetrexed 8 Leucovorin 8 Irinotecan 8 Fluorouracil 8 Cetuximab 8 Bevacizumab 8 trastuzumab deruxtecan 7 Oxaliplatin 7 Drug Therapy 7 Doxorubicin 7 olaparib 6 cemiplimab 6 abemaciclib 6 Radiotherapy 6 Folfox protocol 6 Docetaxel 6 ribociclib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04817956 2024-02-29

IMPRESS-N

Oslo University Hospital

Phase 2 Recruiting

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡